Changchun High-Tech Industries (Group) Inc. (000661.SZ) Bundle
As investors eye Changchun High‑Tech Industries Inc. (000661.SZ), the balance between resilient liquidity and sharply weakening top‑line and earnings trends demands attention: operating revenue fell to 13.466 billion yuan in 2024 (a 7.55% decline year‑over‑year) with Q1 2025 revenue at 2.997 billion yuan (down 5.66% YoY) amid falling demand and heightened competition in growth‑hormone products, while net profit slid to 2.583 billion yuan in 2024 (a 43.01% drop) and Q1 2025 net was 473 million yuan (down 44.95% YoY) driving the net profit margin down to 14.11% in H1 2025 from 32.79% in 2023; offsetting pressures include a conservative capital structure-debt‑to‑equity at 0.08 with a current ratio of 3.85 and quick ratio of 2.12, and an interest coverage of 41.45-but valuation multiples are rich (P/E ~39.85, EV/EBITDA 16.40, EV/Sales 2.97, EV/FCF -30.87) even as foreign sales jumped 454% to 99 million yuan in 2024 and the company plans nearly 8 billion yuan in innovative drug R&D over four years, all while risks from procurement policies, new entrants, subsidiary underperformance, rising expenses (sales, management and finance costs reaching 46.97% of revenue in 2025) and a 133 million yuan impairment from a terminated U.S. long‑acting growth hormone filing loom large-read on to see how these numbers translate into investor implications.
Changchun High-Tech Industries Inc. (000661.SZ) - Revenue Analysis
- Operating revenue in 2024: 13.466 billion yuan (down 7.55% year‑on‑year).
- Revenue in Q1 2025: 2.997 billion yuan (down 5.66% year‑on‑year).
- Primary drivers of decline: weaker demand for growth hormone products and intensified competition.
- Real estate segment revenue fell 17.32% in 2024.
- Foreign sales rose 454% to 99 million yuan in 2024, but were insufficient to offset domestic declines.
- Trend in revenue growth rate: 15.35% (2022) → [implied 2023 value omitted] → -7.56% (2024), indicating a sharp deceleration in top‑line momentum.
| Metric | 2022 | 2023 | 2024 | Q1 2025 |
|---|---|---|---|---|
| Operating Revenue (billion yuan) | - | - | 13.466 | 2.997 |
| YoY Growth Rate | 15.35% | - | -7.56% (or -7.55% reported) | -5.66% (Q1) |
| Foreign Sales (million yuan) | - | - | 99 | - |
| Real Estate Segment Change | - | - | -17.32% | - |
- Segment note: pharmaceuticals (notably growth hormone) drive a large share of revenue - sensitivity to demand shifts and competitive pricing has translated into the recent declines.
- Offsetting factor: rapid expansion in export sales (454% increase) shows potential geographic diversification but remains a small absolute base (99 million yuan).
Changchun High-Tech Industries Inc. (000661.SZ) - Profitability Metrics
Recent profitability indicators for Changchun High-Tech Industries Inc. show a marked deterioration driven by weakening product demand and intensifying competition in core therapeutic areas.
- Net profit (2024): ¥2.583 billion - down 43.01% vs. 2023.
- Q1 2025 net profit: ¥473 million - down 44.95% year-on-year.
- Net profit margin: 32.79% in 2023 → 14.11% in 1H2025.
- Net profit growth rate trend: 33.48% (2021) → -40.67% (2024).
- Primary drivers: reduced demand for growth hormones and heightened competitive pressure reducing pricing and volumes.
| Period | Net Profit (¥ billion) | YoY Change (%) | Net Profit Margin (%) |
|---|---|---|---|
| 2021 | N/A | +33.48 | N/A |
| 2023 | ¥4.533 | N/A | 32.79 |
| 2024 | ¥2.583 | -43.01 | N/A |
| Q1 2025 | ¥0.473 | -44.95 | N/A |
| 1H 2025 | N/A | N/A | 14.11 |
- Implications for margins and earnings quality:
- Margin compression (32.79% → 14.11%) signals weaker pricing power and/or higher relative costs.
- Sharp YoY declines in net profit and quarterly performance indicate cyclical or structural demand loss in growth hormone products.
- Near-term monitoring priorities:
- Revenue recovery or stabilization in core biologics segments.
- Cost control and gross margin improvements.
- Competitive dynamics and pricing trends for growth hormones.
Related company positioning and long-term strategic direction: Mission Statement, Vision, & Core Values (2026) of Changchun High-Tech Industries (Group) Inc.
Changchun High-Tech Industries Inc. (000661.SZ) - Debt vs. Equity Structure
Changchun High-Tech Industries Inc. (000661.SZ) exhibits a conservative capital structure characterized by very low leverage and strong short-term liquidity. The company's low debt levels provide flexibility for strategic investments, dividend policy maintenance, or navigating cyclical pressures without relying heavily on external borrowing. High coverage of interest expenses further reduces refinancing and solvency risks.- Debt-to-Equity Ratio: 0.08 - indicates minimal reliance on debt financing and low financial risk.
- Current Ratio: 3.85 - shows strong ability to meet short-term obligations with current assets.
- Quick Ratio: 2.12 - confirms sufficient liquid assets available to cover immediate liabilities.
- Interest Coverage Ratio: 41.45 - reflects ample earnings to service interest expenses comfortably.
| Metric | Value | What it indicates |
|---|---|---|
| Debt-to-Equity Ratio | 0.08 | Very low leverage; conservative financing and limited creditor exposure. |
| Current Ratio | 3.85 | Strong short-term liquidity; cushion against working capital shocks. |
| Quick Ratio | 2.12 | Immediate obligations can be covered without relying on inventory conversion. |
| Interest Coverage Ratio | 41.45 | High capability to meet interest expenses; low default risk from interest burden. |
| Implication for Financial Flexibility | High | Capacity to pursue M&A, capex, or shareholder returns without heavy new borrowing. |
Changchun High-Tech Industries Inc. (000661.SZ) - Liquidity and Solvency
Changchun High-Tech Industries Inc. (000661.SZ) demonstrates robust short-term liquidity and conservative leverage, underpinned by a current ratio of 3.85 and a quick ratio of 2.12. These metrics indicate ample capacity to cover immediate and near-term obligations without reliance on inventory liquidation. The interest coverage ratio stands at 41.45, reflecting a strong ability to service interest expenses from operating earnings. Combined with low overall debt levels and a low debt-to-equity ratio, the company's financial position affords notable flexibility and reduced financial risk.- Current ratio: 3.85 - strong short-term financial health.
- Quick ratio: 2.12 - sufficient liquidity to cover immediate obligations.
- Interest coverage ratio: 41.45 - excellent capacity to meet interest expenses.
- Low debt and low debt-to-equity ratio - conservative financing and low financial risk.
- Liquidity ratios collectively indicate a strong ability to meet short-term obligations.
| Metric | Value | Implication |
|---|---|---|
| Current Ratio | 3.85 | Strong cushion for short-term liabilities |
| Quick Ratio | 2.12 | Can cover immediate obligations without inventory |
| Interest Coverage Ratio | 41.45 | Very low risk of interest payment strain |
| Debt-to-Equity Ratio | Low (conservative) | Limited leverage; financial flexibility |
| Total Debt Level | Low | Reduced default and refinancing risk |
Changchun High-Tech Industries Inc. (000661.SZ) - Valuation Analysis
Changchun High-Tech Industries Inc. (000661.SZ) currently exhibits valuation metrics that point to a premium market assessment relative to its book value, earnings and sales, while cash flow metrics raise caution.- P/TBV: 1.84 - market values equity at 1.84× book value.
- EV/EBITDA: 16.40 - implies the enterprise value is 16.4× its operating cash earnings proxy.
- EV/FCF: -30.87 - negative free cash flow (FCF) leading to a negative ratio.
- EV/Sales: 2.97 - enterprise value roughly 3× annual sales.
- P/E: 39.85 - price-to-earnings multiple near 40×.
| Metric | Value | Immediate Implication |
|---|---|---|
| P/TBV | 1.84 | Equity priced at a meaningful premium to book; investor willingness to pay for intangibles/growth. |
| EV/EBITDA | 16.40 | Moderately elevated relative to many industrial peers; suggests limited margin for valuation haircut without earnings improvement. |
| EV/FCF | -30.87 | Negative FCF - company burning cash or investing heavily; valuation based on expectations rather than current cash generation. |
| EV/Sales | 2.97 | Enterprise value approaches 3× revenue, signaling growth expectations or high margin assumptions. |
| P/E | 39.85 | High earnings multiple - market pricing in substantial future profit growth or limited near-term EPS visibility. |
- Premium valuation vs. earnings and sales: P/E ~39.85 and EV/Sales ~2.97 indicate investors are paying up for expected growth or superior margins.
- Cash-flow red flag: EV/FCF at -30.87 signals negative FCF - verify capex, working capital trends, and one-off items driving the negative figure.
- Balance of book vs. market: P/TBV 1.84 shows a sizeable goodwill/intangible premium; assess ROE and asset write-ups.
Changchun High-Tech Industries Inc. (000661.SZ) - Risk Factors
- Declining demand for growth hormone products driven by demographic trends: China's falling birth rate reduces addressable market for pediatric and growth-related therapeutics, pressuring unit volumes and long-term CAGR for core products.
- Procurement policy-driven price compression: Implementation of centralized procurement and provincial procurement mechanisms has introduced explicit price ceilings and increased margin pressure on hormone and biologics lines.
- Competitive incursions eroding market share: New and aggressive entrants such as Weisheng Pharmaceuticals and multinational players (e.g., Novo Nordisk) are competing on price, service and formulation innovations, fragmenting historical market dominance.
- Operational underperformance at key subsidiaries: Baike Biological and Huakang Pharmaceutical have reported declining operating metrics and profitability, reducing consolidated earnings contribution.
- Rising operating expenses: In 2025, combined sales, administrative and finance expenses reached 46.97% of revenue, materially compressing operating margin and free cash flow potential.
- R&D and international development setbacks: Termination of the U.S. application for the long-acting growth hormone led to a one-time impairment of RMB 133 million, reducing asset value and signalling elevated clinical and regulatory risk.
| Risk Category | Quantified Impact / Metric | Timing / Notes |
|---|---|---|
| Demographic demand decline | Lower addressable market; national birth rate decline (macro) | Ongoing; reduces long-term volume growth |
| Procurement price controls | Price compression across provinces; margins under pressure | Implemented progressively since recent procurement rounds |
| Competition (Weisheng, Novo Nordisk) | Market share erosion (company reports indicate share declines in core segments) | Active since 2023-2025; intensified in 2024-25 |
| Subsidiary underperformance | Baike Biological & Huakang: declining revenue and profitability (material to consolidated results) | 2024-2025 period deterioration |
| Expense escalation | Sales + Admin + Finance expenses = 46.97% of revenue | Fiscal year 2025 |
| Impairment from terminated U.S. filing | RMB 133 million impairment recorded | Termination of long-acting growth hormone U.S. application (recent) |
- Cash-flow sensitivity: elevated SG&A (46.97% of revenue in 2025) plus one-off impairments increases reliance on operational cash conversion and working capital management.
- Regulatory and reimbursement risk: provincial procurement and NRDL/reimbursement shifts can quickly alter pricing and uptake for hormone therapies.
- Concentration risk: heavy reliance on growth hormone franchise-any volume or price shock disproportionately affects consolidated profitability.
- R&D execution risk: failed or delayed filings (e.g., U.S. termination) result in asset write-downs and lost future revenue streams.
- Counterparty and subsidiary risk: continued poor performance at Baike Biological and Huakang could necessitate further provisions or restructuring.
Changchun High-Tech Industries Inc. (000661.SZ) - Growth Opportunities
Changchun High-Tech Industries Inc. (000661.SZ) is positioning for multi-year growth driven by heavy R&D investment, international partnerships, product diversification, and expanding overseas sales. Key quantitative indicators underline this trajectory and highlight where investor upside may emerge.- R&D investment: nearly ¥8.0 billion invested in innovative drug research over the past four years, supporting late-stage pipeline progression and platform capabilities.
- International collaboration: strategic partnership with Denmark's ALK-Abelló A/S to co-develop desensitization treatment products, enhancing allergy/immunotherapy portfolio and tech transfer potential.
- Overseas expansion: overseas revenue reached ¥99 million in 2024, reflecting initial traction in foreign markets and a baseline for scaling export-driven growth.
- Product pipeline diversification: active development of vaccines and therapies across multiple indications to reduce dependence on legacy growth-hormone revenues.
- Operational focus: initiatives to improve R&D efficiency, tighten clinical timelines, and accelerate regulatory filings to convert pipeline value into commercial revenues.
| Metric | Value / Status |
|---|---|
| Four-year R&D investment | ≈ ¥8,000 million |
| 2024 overseas revenue | ¥99 million |
| Key international partner | ALK-Abelló A/S (Denmark) |
| Core diversification focus | Vaccines, desensitization treatments, novel biologics |
| Primary risk mitigant | Reduce reliance on growth hormones via new product launches |
| R&D efficiency actions | Portfolio prioritization, accelerated clinical pathways, external partnerships |
- New-product development roadmap: advancing vaccine candidates and specialty biologics with staged clinical milestones planned over 2025-2028.
- Commercial playbook: leverage partnerships (e.g., ALK-Abelló) for co-development/commercialization and use incremental overseas sales (¥99M in 2024) to validate export channels.
- Financial leverage: continued R&D spending balanced by targeted cost control in non-core areas to preserve margins while funding pipeline advancement.
Changchun High-Tech Industries (Group) Inc. (000661.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.